Researchers at the Hellenic Cancer Society and the Biomedical Research Foundation, Academy of Athens in Greece conducted a review on exhaled breath condensate analysis as a tool to assess lung function in patients with respiratory disorders. The study was recently published in The Scientific World…
News
Jason van’t Slot — a 20-year-old South African — was born with Cystic Fibrosis, and after receiving a prognosis of a 10-year life span at the age of 8 months, celebrated his 20th year of living with CF by cycling the beguiling and grueling ABSA Cape Epic — the toughest…
Coughing, wheezing, breathlessness during exercise, and increased sputum production are typical cystic fibrosis symptoms. However, these are also the symptoms of a complication that affects cystic fibrosis patients, termed allergic bronchopulmonary aspergillosis (ABPA). According to the Cystic Fibrosis Foundation, children affected by ABPA are allergic to the…
Garden Grove, California based Novoteris, LLC has received $2.8 million in funding from Cystic Fibrosis Foundation Therapeutics Inc. (CFFT) to develop an inhaled nitric oxide antimicrobial therapy for people with cystic fibrosis (CF) who have airway bacterial colonization. CFFT is the nonprofit drug discovery and development affiliate of the Cystic…
A new study on the clinical outcomes of cystic fibrosis revealed that patients infected only by Staphylococcus aureus infection in the absence of Pseudomonas aeruginosa led to milder disease. The study entitled “Clinical outcomes associated with Staphylococcus aureus and Pseudomonas aeruginosa airway infections in adult cystic fibrosis patients” was published…
Boulder, Colorado based Nivalis Therapeutics, Inc., a clinical stage pharmaceutical company focused on treating people with cystic fibrosis (CF), recently announced its initial public offering (IPO) which included 5.5 million shares of common stock priced at $14.00 per share before underwriting discounts and commissions. Nivalis additionally granted underwriters a 30-day option…
Laurent Pharmaceuticals Inc., a Montréal-based private biopharmaceutical company currently developing a clinical stage lipid modulator (LAU-7b) designed to address the compromised immune-inflammatory response in Cystic Fibrosis (CF), recently announced positive data from its Phase 1b study that assessed LAU-7b in adult patients with CF. LAU-7b is a novel…
Pulmatrix, Inc., a biopharmaceutical company focused on inhaled therapies for serious pulmonary diseases, recently announced a new drug candidate called PUR1900 for the treatment of fungal infections associated with cystic fibrosis (CF). CF is a rare, life-threatening genetic disease in which a defective gene (CFTR) induces a salt imbalance, causing…
The five-year survival rate for Canadians with cystic fibrosis who have received a lung transplant is 67% and half of those who have had transplants live beyond 10 years, new research has found. The encouraging statistics were published today in the Journal of Heart Lung Transplantation by…
Protalix BioTherapeutics, Inc. recently announced that on June 12, 2015 Dr. Yosehp Shaaltiel, EVP of Research and Development, presented pre-clinical data on the company’s AIR DNaseTM (PRX-110) for cystic fibrosis (CF) treatment at the 38th European Cystic Fibrosis Conference, held in Brussels, Belgium. The oral presentation was entitled…
Your CF Community
Visit the Cystic Fibrosis News Today forums to connect with others in the CF community.